氨茶堿與甲潑尼龍琥珀酸鈉聯(lián)合治療慢性阻塞性肺病急性 加重期的臨床效果及對(duì)血清CRP水平、 PaO2 的影響
關(guān)鍵詞:氨茶堿;甲潑尼龍琥珀酸鈉;慢性阻塞性肺病急性加重期;CRP; PaO2 中圖分類號(hào):R563 文獻(xiàn)標(biāo)識(shí)碼:A
DOI:10.3969/j.issn.1006-1959.2025.13.030 文章編號(hào):1006-1959(2025)13-0150-04
Abstract:OectieTexplotlcalofmioyineobdielpredsoloesodmsucateintreafte exacerbation of chronic obstructive pulmonary disease and its effect on serum CRP level and PaO2. Methods A total of 6O patients with acute exacerbationofronctructiepulmoardseaseadmitedtoYushanCountyHuanisiHospitalfroMa1toMa24weeeletd theresearcectscodingtoeadomumberablemetod,teyeredvidedintocontrolgounddyoup,ith3Opatitsc group.Thecotroloupastreaedwitnohlnendtesdopsreadwitethlpredsoloeucateoef thecontrolgoiddiaiti capacityinthefirstsecondtoforcedvitalcapacity(FEV/FCV),seruminflammatoryfactorlevels[tumornecrosisfactor ??α∝ (TNF-α),interleukin-8 (IL-8),procalcitonin (PCT),C-reactive protein (CRP)], blood gas index levels ?pH ,arterial partial pressure of carbon dioxide (PaCO2),arterial partial pressure of oxygen (Pa02)- werecomparedbetweenthetwogroups.ResultsThetotalefectiverateof treatmentinthestudygroupwashigherthan that in the control group( P<0.05) .Thelung function indexes of the study group were better than those of the control group( P<0.05) .Thelevelsof serum inflammatory factors in the study group were lower than those inthe control group( P<0.05) .The level of PaCO2 in the study group was lower than that in the control group,while the level of PaO2 was higher than that in the control group (P<0.05) .Conclusion The combination of aminophyllneandethlpredisolosoduciateasadefinitecliicalectitetrmentofpatintsitacueeacbationf chronicobstructivepulmonarydiseasehichcanimprovetheungfuctionofpatients,educetheilammatoryesponseofpatientspoe the clinical effectand bloodgasindexlevel,andisworthyof clinical application.
Keywords:Aminophyline;Methylprednsolonesodiumsuinate;Acuteexacerbationofchronicobstructivepulmonarydisease;CRP; PaO2
慢阻肺(chronic obstructive pulmonary disease,COPD)在臨床中極為常見(jiàn)。(剩余5654字)
-
-
- 醫(yī)學(xué)信息
- 2025年13期
- 基于文獻(xiàn)計(jì)量學(xué)的人工智能在中醫(yī)...
- 護(hù)理信息系統(tǒng)創(chuàng)新性使用行為的影...
- 智能化集成式綜合預(yù)約平臺(tái)的建設(shè)...
- 阜陽(yáng)地區(qū)乳腺癌患者腋窩淋巴結(jié)轉(zhuǎn)...
- 基于CiteSpace的慢性骨...
- 玉女煎治療糖尿病臨床療效和安全...
- 基于VOSviewer的ERC...
- 維持性血液透析患者自體動(dòng)靜脈內(nèi)...
- ORCID在醫(yī)學(xué)類中國(guó)科技核心...
- 臨床醫(yī)學(xué)完全開(kāi)放獲取期刊的特征...
- 大數(shù)據(jù)時(shí)代基于InCites及...
- 2020年1月-2022年12...
- 智能手機(jī)成癮對(duì)中國(guó)成年人乳腺癌...
- 醫(yī)院服務(wù)應(yīng)用管理系統(tǒng)的設(shè)計(jì)與應(yīng)...
- 基于對(duì)標(biāo)理論的綜合不良事件管理...
- 科研信息化在醫(yī)院科研人員績(jī)效考...
- 基于孟德?tīng)栯S機(jī)化方法分析炎癥性...
- 不同劑量布地奈德霧化吸入對(duì)老年...
- 左炔諾孕酮宮內(nèi)節(jié)育系統(tǒng)聯(lián)合屈螺...
- 阿奇霉素聯(lián)合布地奈德霧化治療小...
- 進(jìn)展性Wellens綜合征相關(guān)...
- 小骨窗開(kāi)顱術(shù)與鉆孔引流術(shù)治療高...
- 舒芬太尼配伍羅哌卡因椎管內(nèi)麻醉...
- 乙酰半胱氨酸泡騰片聯(lián)合布地奈德...
- 替格瑞洛聯(lián)合阿司匹林、阿托伐他...
- 阿莫西林聯(lián)合奧美拉唑治療胃炎合...
- 硬通道鉆孔引流術(shù)對(duì)慢性硬膜下血...
- 不同劑量利伐沙班治療老年心力衰...
- 桑芩止咳湯聯(lián)合定喘湯加減治療慢...
- 氨茶堿與甲潑尼龍琥珀酸鈉聯(lián)合治...
- CT與MRI在急性腦梗死患者診...
- 益氣化痰方聯(lián)合化療對(duì)肺癌患者毒...
- 超聲引導(dǎo)下頸部迷走神經(jīng)阻滯在胸...
- 利培酮片與富馬酸喹硫平片治療首...
- “人工智能+全病程管理”模式在...
- 中醫(yī)特色護(hù)理在痰喘散穴位敷貼治...
- 4R危機(jī)理論的護(hù)理對(duì)ICU重癥...
- 多樣化護(hù)理措施對(duì)于急性闌尾炎手...
- 精細(xì)護(hù)理在復(fù)雜腎結(jié)石患者行多通...